Smithbridge Asset Management Inc. DE Invests $3.41 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Smithbridge Asset Management Inc. DE bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,368 shares of the biopharmaceutical company's stock, valued at approximately $3,405,000.

Several other institutional investors have also recently made changes to their positions in REGN. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $25,000. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $28,000. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. Tompkins Financial Corp bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $32,000. Institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on REGN. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $700.00 to $580.00 in a research note on Friday, May 30th. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a research note on Monday, June 2nd. UBS Group decreased their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Finally, Royal Bank of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research note on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $7.40 during trading on Friday, hitting $529.24. 951,512 shares of the stock traded hands, compared to its average volume of 877,247. The company has a market capitalization of $57.14 billion, a P/E ratio of 13.83, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The firm has a 50-day simple moving average of $563.74 and a 200-day simple moving average of $651.53. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $9.55 EPS. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.